A trial fibrillation (AF) is the most common sustained clinical arrhythmia and its incidence is increasing with projections exceeding 10 million by 2050 (1). It is associated with increased mortality and morbidity, the most devastating outcome being thromboembolic stroke. AF is detectable in 25% to 30% of patients with cryptogenic stroke (2-4), and the concept of AF as a direct cause of stroke has been a long-standing tenant in the practice of medicine. However, AF is also highly associated with increasing age and comorbidities that are independent causes of stroke (e.g., hypertension). As 
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B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N P U B L I S H E D B Y E L S E V I E R
The association among AF, comorbidities, and stroke is unequivocal and has been recognized for decades, but the relative contribution of each remains unknown. Determining the underlying cause(s) of this inflammatory, profibrotic, and prothrombotic state in patients with "lone AF" and no other "comorbidity" is critical for our understanding. In the meantime, the old question remains whether AF is an innocent bystander that is a marker of comorbidity severity or a guilty accomplice that contributes to thrombogenesis.
